Cargando…

Prodromal headache in anti‐NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity

OBJECTIVE: To investigate the nature of prodromal headache in anti‐NMDA receptor (NMDAR) encephalitis. METHODS: Retrospective review of the clinical information of 39 patients with anti‐NMDAR encephalitis admitted between January 1999 and September 2017. Five patients with an atypical presentation w...

Descripción completa

Detalles Bibliográficos
Autores principales: Tominaga, Naomi, Kanazawa, Naomi, Kaneko, Atsushi, Kaneko, Juntaro, Kitamura, Eiji, Nakagawa, Hiroto, Nishiyama, Kazutoshi, Iizuka, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043713/
https://www.ncbi.nlm.nih.gov/pubmed/29856136
http://dx.doi.org/10.1002/brb3.1012
_version_ 1783339340038930432
author Tominaga, Naomi
Kanazawa, Naomi
Kaneko, Atsushi
Kaneko, Juntaro
Kitamura, Eiji
Nakagawa, Hiroto
Nishiyama, Kazutoshi
Iizuka, Takahiro
author_facet Tominaga, Naomi
Kanazawa, Naomi
Kaneko, Atsushi
Kaneko, Juntaro
Kitamura, Eiji
Nakagawa, Hiroto
Nishiyama, Kazutoshi
Iizuka, Takahiro
author_sort Tominaga, Naomi
collection PubMed
description OBJECTIVE: To investigate the nature of prodromal headache in anti‐NMDA receptor (NMDAR) encephalitis. METHODS: Retrospective review of the clinical information of 39 patients with anti‐NMDAR encephalitis admitted between January 1999 and September 2017. Five patients with an atypical presentation were excluded. Thus, in 34 patients (median 27 years [range, 12–47 years]; 28 [82%] female), the clinical features were compared between patients who initially reported headache and those who did not report. RESULTS: Twenty‐two patients (65%) reported headache either transiently (n = 5) or continuously (n = 17). Encephalitic symptoms (psychobehavioral memory alterations, seizure, dyskinesias, or altered level of consciousness) developed in 20 patients with median 5.5 days (range, 1‐29 days) after headache onset. In one patient, NMDAR antibodies were detected in CSF 3 days after headache onset. Patients with headache had more frequently fever (14/22 [64%] vs. 2/12 [17%] p = 0.013) and higher CSF pleocytosis (median white blood cells 79/μl [range, 6‐311/μl] vs. 30/μl [range, 2‐69/μl], p = 0.035) than those without headache, but there was no difference in gender, age at onset, seizure, migraine, CSF oligoclonal band detection, elevated IgG index, tumor association, or brain MRI abnormalities between them. CONCLUSIONS: Headache often developed with fever and pleocytosis, but it was rapidly replaced by psychiatric symptoms. Based on current knowledge on the antibody‐mediated mechanisms that cause a decrease of synaptic NMDAR through crosslinking and internalization leading to a state mimicking “dissociative anesthesia,” we speculated that prodromal headache is not likely caused by direct effect of the autoantibodies but rather meningeal inflammation (noninfectious aseptic meningitis) that occurs in parallel to intrathecal antibody synthesis as an epiphenomenon of NMDAR autoimmunity. Psychobehavioral alterations following headache is an important clue to the diagnosis.
format Online
Article
Text
id pubmed-6043713
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60437132018-07-15 Prodromal headache in anti‐NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity Tominaga, Naomi Kanazawa, Naomi Kaneko, Atsushi Kaneko, Juntaro Kitamura, Eiji Nakagawa, Hiroto Nishiyama, Kazutoshi Iizuka, Takahiro Brain Behav Original Research OBJECTIVE: To investigate the nature of prodromal headache in anti‐NMDA receptor (NMDAR) encephalitis. METHODS: Retrospective review of the clinical information of 39 patients with anti‐NMDAR encephalitis admitted between January 1999 and September 2017. Five patients with an atypical presentation were excluded. Thus, in 34 patients (median 27 years [range, 12–47 years]; 28 [82%] female), the clinical features were compared between patients who initially reported headache and those who did not report. RESULTS: Twenty‐two patients (65%) reported headache either transiently (n = 5) or continuously (n = 17). Encephalitic symptoms (psychobehavioral memory alterations, seizure, dyskinesias, or altered level of consciousness) developed in 20 patients with median 5.5 days (range, 1‐29 days) after headache onset. In one patient, NMDAR antibodies were detected in CSF 3 days after headache onset. Patients with headache had more frequently fever (14/22 [64%] vs. 2/12 [17%] p = 0.013) and higher CSF pleocytosis (median white blood cells 79/μl [range, 6‐311/μl] vs. 30/μl [range, 2‐69/μl], p = 0.035) than those without headache, but there was no difference in gender, age at onset, seizure, migraine, CSF oligoclonal band detection, elevated IgG index, tumor association, or brain MRI abnormalities between them. CONCLUSIONS: Headache often developed with fever and pleocytosis, but it was rapidly replaced by psychiatric symptoms. Based on current knowledge on the antibody‐mediated mechanisms that cause a decrease of synaptic NMDAR through crosslinking and internalization leading to a state mimicking “dissociative anesthesia,” we speculated that prodromal headache is not likely caused by direct effect of the autoantibodies but rather meningeal inflammation (noninfectious aseptic meningitis) that occurs in parallel to intrathecal antibody synthesis as an epiphenomenon of NMDAR autoimmunity. Psychobehavioral alterations following headache is an important clue to the diagnosis. John Wiley and Sons Inc. 2018-06-01 /pmc/articles/PMC6043713/ /pubmed/29856136 http://dx.doi.org/10.1002/brb3.1012 Text en © 2018 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Tominaga, Naomi
Kanazawa, Naomi
Kaneko, Atsushi
Kaneko, Juntaro
Kitamura, Eiji
Nakagawa, Hiroto
Nishiyama, Kazutoshi
Iizuka, Takahiro
Prodromal headache in anti‐NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity
title Prodromal headache in anti‐NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity
title_full Prodromal headache in anti‐NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity
title_fullStr Prodromal headache in anti‐NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity
title_full_unstemmed Prodromal headache in anti‐NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity
title_short Prodromal headache in anti‐NMDAR encephalitis: An epiphenomenon of NMDAR autoimmunity
title_sort prodromal headache in anti‐nmdar encephalitis: an epiphenomenon of nmdar autoimmunity
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043713/
https://www.ncbi.nlm.nih.gov/pubmed/29856136
http://dx.doi.org/10.1002/brb3.1012
work_keys_str_mv AT tominaganaomi prodromalheadacheinantinmdarencephalitisanepiphenomenonofnmdarautoimmunity
AT kanazawanaomi prodromalheadacheinantinmdarencephalitisanepiphenomenonofnmdarautoimmunity
AT kanekoatsushi prodromalheadacheinantinmdarencephalitisanepiphenomenonofnmdarautoimmunity
AT kanekojuntaro prodromalheadacheinantinmdarencephalitisanepiphenomenonofnmdarautoimmunity
AT kitamuraeiji prodromalheadacheinantinmdarencephalitisanepiphenomenonofnmdarautoimmunity
AT nakagawahiroto prodromalheadacheinantinmdarencephalitisanepiphenomenonofnmdarautoimmunity
AT nishiyamakazutoshi prodromalheadacheinantinmdarencephalitisanepiphenomenonofnmdarautoimmunity
AT iizukatakahiro prodromalheadacheinantinmdarencephalitisanepiphenomenonofnmdarautoimmunity